Inogen Names Kristin Caltrider as Chief Financial Officer
March 04 2022 - 6:00AM
Business Wire
Inogen, Inc. (NASDAQ: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today announced the appointment of Kristin Caltrider as
EVP & Chief Financial Officer, effective March 21, 2022. Ms.
Caltrider succeeds Mike Sergesketter, who joined the Company as
interim CFO in December 2021, and will remain with Inogen through
June 24, 2022 to facilitate a smooth transition.
Nabil Shabshab, President and Chief Executive Officer of Inogen,
said, “Kristin is a proven executive who brings deep experience in
leading the financial operations of healthcare businesses. She has
a clear track record of partnering cross functionally to
successfully develop strategic plans and execute against a clear
set of financial and business goals to add scale and drive
profitable growth. The Board and I are thrilled that she is joining
us at such a pivotal time, as we work to continue the
transformation of Inogen into a respiratory care MedTech leader,
with durable performance and profitability.”
Ms. Caltrider said, “Inogen is on a great trajectory and it’s an
exciting time to join the Company. Inogen has a wealth of talent
and a clear opportunity to build on its strong platform and drive
value for patients and investors alike. I look forward to working
with the Board, Nabil and the rest of the management team to
execute on the strategic plan and work to position the Company for
sustainable, long-term growth.”
Mr. Shabshab continued, “I want to thank Mike for his steady
support during our search process for a CFO – I am grateful for his
willingness to come out of retirement to support Inogen and for
bringing his experience and discipline to bear which we have
benefited from greatly.”
Kristin A. Caltrider Biography
Ms. Caltrider joins Inogen from Quidel Corporation, a provider
of rapid diagnostic testing solutions, cellular-based virology
assays and molecular diagnostic systems listed on NASDAQ, where she
most recently served as Vice President of Finance since June 2014.
In this role, Ms. Caltrider oversaw global Finance and Accounting
functions, which included all aspects of transactional and
technical accounting, tax and treasury, financial planning and
analysis, cash management and forecasting, finance-related M&A
activities as well as global analytics, and sales operations. While
in that role, she helped the company aggressively scale its
manufacturing capacity and significantly expand revenue and
profitability. Ms. Caltrider first joined Quidel in 2007, where she
held roles of increasing responsibility. Prior to joining Quidel,
Ms. Caltrider spent almost four years at Life Technologies (now
Thermo Fisher), where she held a number of positions. Ms. Caltrider
graduated from California Lutheran University with a bachelor’s
degree in Business Administration, and also holds an MBA from the
University of San Diego.
About Inogen
We are a medical technology company offering innovative
respiratory products for use in the homecare setting. We primarily
develop, manufacture and market innovative portable oxygen
concentrators used to deliver supplemental long-term oxygen therapy
to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements with respect to the
announced changes to management; statements concerning or implying
Inogen’s future financial performance; statements regarding
Inogen’s goals and potential, including the potential for Inogen to
achieve durable performance and profitability; the ability of
management personnel to contribute to the execution of Inogen’s
strategic plans and goals; and the ability of Inogen to achieve
sustainable, long-term growth. Any statements contained in this
communication that are not statements of historical fact may be
deemed to be forward-looking statements. Words such as “believes,”
“anticipates,” “plans,” “expects,” “will,” “intends,” “potential,”
“possible,” and similar expressions are intended to identify
forward-looking statements. Forward-looking statements are subject
to numerous risks and uncertainties that could cause actual results
to differ materially from currently anticipated results, including
but not limited to, risks related to its announced management and
organizational changes, and risks arising from the possibility that
Inogen will not realize anticipated future financial performance or
strategic goals. In addition, Inogen's business is subject to
numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of its products;
competition; its sales, marketing and distribution capabilities;
its planned sales, marketing, and research and development
activities; interruptions or delays in the supply of components or
materials for, or manufacturing of, its products; seasonal
variations; unanticipated increases in costs or expenses; and risks
associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting
Inogen’s business operating results are contained in its Annual
Report on Form 10-K for the period ended December 31, 2021, and in
its other filings with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof.
Inogen disclaims any obligation to update these forward-looking
statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220304005101/en/
Investor and Media Contacts Bryan Locke, Mike DeGraff,
Gabriella Coffey ir@inogen.net
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Apr 2023 to Apr 2024